Posted by Michael Wonder on 09 Jun 2020
BioCryst announces berotralstat expanded access program for patients with hereditary angioedema in United States
9 June 2020 - BioCryst Pharmaceuticals today announced that the company has established an expanded access program with oral, once-daily berotralstat, an investigational drug, for patients with hereditary angioedema in the United States.
Through this program, physicians may be able to request berotralstat for hereditary angioedema patients who do not have access to the product through a clinical trial.
